Schön S, Huep G, Prante C, Müller S, Christ R, Hagena F-W, Kuhn J, Kleesiek K, Götting C
Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
Osteoarthritis Cartilage. 2006 May;14(5):442-8. doi: 10.1016/j.joca.2005.11.004. Epub 2005 Dec 22.
The hallmark in osteoarthritis (OA) is the loss of proteoglycans (PGs) in articular cartilage (AC). Xylosyltransferase I (XT-I) catalyzes the transfer of xylose to serine residues in the core protein and initiates the biosynthesis of PGs in AC. The XYLT-II gene encodes a highly homologous protein but its biological function is not yet known. Here we investigate for the first time genetic variations in the XYLT-genes and serum XT-I activities and their implication in OA.
Denaturing high-performance liquid chromatography (DHPLC) was used for the screening of the XYLT-genes in 49 OA patients. For a detailed characterization of XT-I amino acid exchanges we performed recombinant expression of XT-I mutants in insect cells. Furthermore, the XT activity was measured in the patients' serum.
The variation c.1569C>T (XYLT-II) occurs with a significantly higher frequency in younger OA patients in comparison with the older ones (P<0.001) and the controls (P<0.02). Furthermore, significantly higher serum XT activities were found in patients with a long disease duration of OA (P<0.04). The recombinant XT-I mutants p.P385L and p.I552S had reduced enzymatic activity (85% and 74%) compared with the wildtype (wt).
Our findings indicate a correlation of the c.1569 T-allele in XYLT-II with an earlier manifestation of OA and that the serum XT activity is a potential biochemical marker for staging and monitoring the progression of AC damage in OA. Comparison of XT-I activity in mutant enzymes in vivo and in vitro revealed that heterozygous mutations are not involved in OA.
骨关节炎(OA)的标志是关节软骨(AC)中蛋白聚糖(PGs)的丢失。木糖基转移酶I(XT-I)催化木糖转移至核心蛋白中的丝氨酸残基,并启动AC中PGs的生物合成。XYLT-II基因编码一种高度同源的蛋白质,但其生物学功能尚不清楚。在此,我们首次研究XYLT基因的遗传变异、血清XT-I活性及其在OA中的意义。
采用变性高效液相色谱(DHPLC)对49例OA患者的XYLT基因进行筛查。为详细表征XT-I氨基酸交换情况,我们在昆虫细胞中对XT-I突变体进行了重组表达。此外,还检测了患者血清中的XT活性。
与老年OA患者(P<0.001)及对照组(P<0.02)相比,变异c.1569C>T(XYLT-II)在年轻OA患者中出现的频率显著更高。此外,OA病程较长的患者血清XT活性显著更高(P<0.04)。与野生型(wt)相比,重组XT-I突变体p.P385L和p.I552S的酶活性降低(分别为85%和74%)。
我们的研究结果表明,XYLT-II中的c.1569 T等位基因与OA的早期表现相关,血清XT活性是OA中AC损伤分期和监测进展的潜在生化标志物。体内和体外突变酶中XT-I活性的比较表明,杂合突变与OA无关。